Prosecution Insights
Prosecution Insights
36 pending office actions • 20 art units • 31 examiners • 0 of 36 (0%) have an AI response strategy ready • 32 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 36 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 36 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (8%) |
| §103 only | 17 (47%) |
| §102 only | 1 (3%) |
| §112 only | 2 (6%) |
| No statute on record | 13 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 2 | 50.4% | +54.3% |
| SULLIVAN, DENNIS JOHN | 2 | 61.0% | +49.9% |
| SANG, HONG | 2 | 54.7% | +61.8% |
| GUSTILO, ESTELLA M | 2 | 52.7% | +33.9% |
| SKOKO III, JOHN JOSEPH | 2 | 52.8% | +58.4% |
| GEDRA, OLIVIA ROSE | 1 | 0.0% | +0.0% |
| HARRINGTON, MICHAEL P | 1 | 24.6% | +17.1% |
| DO, AN H | 1 | 90.6% | +6.8% |
| XIAO, YAN | 1 | 67.9% | +51.5% |
| FAUST, AMBER KATHLEEN | 1 | 62.3% | +50.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17235974 | NEUROLOGIC TOXICITY ASSESSMENT METHODS AND SYSTEMS FOR DOCUMENTING CHANGES IN HANDWRITING | ROBERTS, ANNA L | 164d overdue |
| 18553272 | DRUG MATERIAL INTERACTIONS USING QUARTZ CRYSTAL MICROBALANCE SENSORS | DO, AN H | 25d overdue |
| 18720427 | ORCHESTRATED PERSONALIZED THERAPY SYSTEMS AND METHODS | GEDRA, OLIVIA ROSE | 9d overdue |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 34d |
| 18596281 | SMART LABEL DEVICES, SYSTEMS, AND METHODS | HARRINGTON, MICHAEL P | 62d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 147d overdue |
| 17980149 | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody | HADDAD, MAHER M | 89d overdue |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 88d overdue |
| 17674397 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | SKOKO III, JOHN JOSEPH | 86d overdue |
| 18300183 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | SULLIVAN, DENNIS JOHN | 70d overdue |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | SKOKO III, JOHN JOSEPH | 49d overdue |
| 18175345 | Methods of Treating High Risk Multiple Myeloma | SANG, HONG | 10d overdue |
| 16797301 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | SANG, HONG | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1646 | 7 |
| 1642 | 4 |
| 1674 | 4 |
| 1643 | 3 |
| 1641 | 2 |
| 1682 | 2 |
| 3681 | 1 |
| 3628 | 1 |
| 2853 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720427 | ORCHESTRATED PERSONALIZED THERAPY SYSTEMS AND METHODS | GEDRA, OLIVIA ROSE | 3681 | §103 | Final Rejection | 9d overdue | Pending | Jun 14, 2024 |
| 18596281 | SMART LABEL DEVICES, SYSTEMS, AND METHODS | HARRINGTON, MICHAEL P | 3628 | §103 | Final Rejection | 62d | Pending | Mar 05, 2024 |
| 18553272 | DRUG MATERIAL INTERACTIONS USING QUARTZ CRYSTAL MICROBALANCE SENSORS | DO, AN H | 2853 | §101 | Non-Final OA | 25d overdue | Pending | Sep 29, 2023 |
| 18552504 | ANTI-TAU ANTIBODIES AND USES THEREOF | XIAO, YAN | 1642 | Other | Non-Final OA | 28d | Pending | Sep 26, 2023 |
| 18284209 | HUMANIZED ANTIBODIES AGAINST PAIRED HELICAL FILAMENT TAU AND USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | Other | Non-Final OA | 29d | Pending | Sep 26, 2023 |
| 18549665 | USES OF CD79B ANTIBODIES FOR AUTOIMMUNE THERAPEUTIC APPLICATIONS | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | 19d | Pending | Sep 08, 2023 |
| 18344973 | MATERIALS AND METHODS FOR BIOENGINEERED IPSC POPULATIONS | CANDELARIA, JULIANA IRENE | 1634 | §103 | Non-Final OA | 21d | Pending | Jun 30, 2023 |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | SULLIVAN, DENNIS JOHN | 1642 | Other | Non-Final OA | 54d | Pending | Jun 29, 2023 |
| 18327577 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA | SAOUD, CHRISTINE J | 1645 | Other | Non-Final OA | 46d | Pending | Jun 01, 2023 |
| 18199007 | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody | LOCKARD, JON MCCLELLAND | 1647 | Other | Non-Final OA | 6d | Pending | May 18, 2023 |
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | 6d | Pending | May 05, 2023 |
| 18300183 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | SULLIVAN, DENNIS JOHN | 1642 | §103 | Final Rejection | 70d overdue | Pending | Apr 13, 2023 |
| 18128310 | Method of Treating Psoriasis with IL-23 Specific Antibody | ABBAS, SYED JARAR | 1674 | Other | Non-Final OA | 88d overdue | Pending | Mar 30, 2023 |
| 18175345 | Methods of Treating High Risk Multiple Myeloma | SANG, HONG | 1646 | Other | Non-Final OA | 10d overdue | Pending | Feb 27, 2023 |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | FORD, VANESSA L | 1674 | Other | Non-Final OA | 17d overdue | Pending | Feb 09, 2023 |
| 18106531 | Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies | REDDIG, PETER J | 1646 | §112 | Final Rejection | 28d | Pending | Feb 07, 2023 |
| 18080639 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | BARRERA, IMMACULADA | 1671 | Other | Non-Final OA | 74d overdue | Pending | Dec 13, 2022 |
| 17980149 | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody | HADDAD, MAHER M | 1641 | §103 | Final Rejection | 89d overdue | Pending | Nov 03, 2022 |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | GUSTILO, ESTELLA M | 1646 | §103 | Non-Final OA | 88d overdue | Pending | Nov 02, 2022 |
| 17918140 | SYSTEMS, MATERIALS, AND METHODS FOR REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC) IDENTIFICATION OF MULTI-SPECIFIC MOLECULES | BERKELEY, EMILY R | 1796 | §103 | Non-Final OA | 20d | Pending | Oct 11, 2022 |
| 17835671 | NUCLEIC ACID CONSTRUCTS ENCODING KALLIKREIN-2 FUSION PROTEIN AND VECTORS, PREPARATIONS OF CELLS, AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | 22d overdue | Pending | Jun 08, 2022 |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | GUSTILO, ESTELLA M | 1646 | §103 | Non-Final OA | 147d overdue | Pending | May 26, 2022 |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | SKOKO III, JOHN JOSEPH | 1643 | Other | Final Rejection | 49d overdue | Pending | May 25, 2022 |
| 17748629 | Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha | PAK, MICHAEL D | 1674 | Other | Non-Final OA | 34d | Pending | May 19, 2022 |
| 17769373 | DYNAMIC MONOSACCHARIDE CONTROL PROCESSES | MOSS, NATALIE M | 1653 | §102 | Final Rejection | 78d | Pending | Apr 15, 2022 |
| 17767263 | MATERIALS AND METHODS FOR MASS SPECTROMETRIC PROTEIN ANALYSIS | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Final Rejection | 9d | Pending | Apr 07, 2022 |
| 17691277 | Methods for Predicting Treatment Response in Ulcerative Colitis | KENNEDY, SARAH JANE | 1682 | §103 | Final Rejection | 72d | Pending | Mar 10, 2022 |
| 17691182 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | GEORGE, DENNIS CHERIAN | 1644 | Other | Non-Final OA | 34d | Pending | Mar 10, 2022 |
| 17691050 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 27d | Pending | Mar 09, 2022 |
| 17674397 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | SKOKO III, JOHN JOSEPH | 1643 | §103 | Final Rejection | 86d overdue | Pending | Feb 17, 2022 |
| 17615959 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | XIE, XIAOZHEN | 1674 | §103 | Final Rejection | 20d | Pending | Dec 02, 2021 |
| 17240609 | Materials and Methods for Treating Juvenile Idiopathic Arthritis | HOLTZMAN, KATHERINE ANN | 1646 | §103 | Final Rejection | 13d | Pending | Apr 26, 2021 |
| 17235974 | NEUROLOGIC TOXICITY ASSESSMENT METHODS AND SYSTEMS FOR DOCUMENTING CHANGES IN HANDWRITING | ROBERTS, ANNA L | 3791 | §101 | Final Rejection | 164d overdue | Pending | Apr 21, 2021 |
| 17182429 | CAPACITY OPTIMIZATION ACROSS DISTRIBUTED MANUFACTURING SYSTEMS | LEE, PO HAN | 3623 | §101 | Non-Final OA | 34d | Pending | Feb 23, 2021 |
| 17005858 | B-CELL MATURATION COMPLEX CAR T CONSTRUCT AND PRIMERS | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 23d | Pending | Aug 28, 2020 |
| 16797301 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | SANG, HONG | 1646 | §103 | Final Rejection | 4d overdue | Pending | Feb 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial